Cue Biopharma (CUE)
Develops immune-modulating biologics for autoimmune and allergic diseases.
$32.07
vs last close+1.17 (+3.79%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
in 49 days
EPS estimate
−$2.24
Revenue estimate
$1.0M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$3.90−$5.11−$2.70−$2.10$0.30−$1.08−$24.14Pending
Estimate−$2.58−$4.20−$3.90−$2.80−$2.70−$3.30−$1.69−$2.24
Surprise−51.2%−21.7%+30.8%+25.0%+111.1%+67.3%−1,328.4%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$1.6M$421.0K$3.0M$2.1M$21.9M$5.7M$7.9MPending
Estimate$1.7M$1.3M$2.0M$2.3M$1.0M$2.5M$3.0M$1.0M
Surprise−7.4%−66.8%+47.7%−6.1%+2,094.2%+127.4%+162.6%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2026 | −$1.76 | — | — |
| Nov 2026 | −$2.24 | — | — |
| Aug 2026 | −$1.69 | −$24.14 | −1,328.4% |
| May 2026 | −$3.30 | −$1.08 | +67.3% |
| Mar 2026 | −$2.70 | $0.30 | +111.1% |
| Nov 2025 | −$2.80 | −$2.10 | +25.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Apr 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Mar 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2026 | −$1.76 | — | — | $1.0M | — | — | — |
| Nov 11, 2026 | −$2.24 | — | — | $1.0M | — | — | — |
| Aug 14, 2026 | −$1.69 | −$24.14 | −1,328.4% | $3.0M | $7.9M | +162.6% | −19.2% |
| May 14, 2026 | −$3.30 | −$1.08 | +67.3% | $2.5M | $5.7M | +127.4% | −14.1% |
| Mar 16, 2026 | −$2.70 | $0.30 | +111.1% | $1.0M | $21.9M | +2,094.2% | +9.9% |
| Nov 12, 2025 | −$2.80 | −$2.10 | +25.0% | $2.3M | $2.1M | −6.1% | −2.2% |
| Aug 12, 2025 | |||||||
| May 12, 2025 | |||||||
| Mar 31, 2025 | |||||||
| Nov 14, 2024 | |||||||
| Aug 19, 2024 | |||||||
| May 9, 2024 | |||||||
| Apr 8, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 9, 2023 | |||||||
| May 9, 2023 | |||||||
| Mar 21, 2023 | |||||||
| Nov 14, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 16, 2022 | |||||||
| Nov 9, 2021 | |||||||
| Aug 9, 2021 | |||||||
| May 17, 2021 | |||||||
| Mar 16, 2021 | |||||||
| Nov 17, 2020 | |||||||
| Aug 7, 2020 | |||||||
| May 7, 2020 | |||||||
| Mar 12, 2020 | |||||||
| Nov 7, 2019 | |||||||
| Aug 8, 2019 | |||||||
| May 8, 2019 | |||||||
| Mar 14, 2019 | |||||||
| Nov 13, 2018 | |||||||
| Aug 13, 2018 | |||||||
| May 14, 2018 | |||||||
| Mar 29, 2018 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 |